CoChat

Targeting p16-induced senescence prevents cigarette smoke-induced emphysema by promoting IGF1/Akt1 signaling in mice

Open access

The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.

Abstract

Senescence is a mechanism associated with aging that alters tissue regeneration by depleting the stem cell pool. Chronic obstructive pulmonary disease (COPD) displays hallmarks of senescence, including a diminished stem cell population. DNA damage from cigarette smoke (CS) induces senescence via the p16 pathway. This study evaluated the contribution of p16 to CS-associated lung pathologies. p16 expression was prominent in human COPD lungs compared with normal subjects. CS induces impaired pulmonary function, emphysema, and increased alveolar epithelial cell (AECII) senescence in wild-type mice, whereas CS-exposed p16 −/− mice exhibit normal pulmonary function, reduced emphysema, diminished AECII senescence, and increased pro-growth IGF1 signaling, suggesting that improved lung function in p16 −/− mice was due to increased alveolar progenitor cell proliferation. In conclusion, our study suggests that targeting senescence may facilitate alveolar regeneration in COPD emphysema by promoting IGF1 proliferative signaling.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s42003-019-0532-1

Cites

59 of 59 references verified0 citation errors · 0 not checkable

Statistics

Figures

Fig. 1 Immunohistochemical localization of p16 in human lungs. p16 (red) and SPC (yellow) staining in a healthy non-smoker, healthy smoker, and b COPD human lungs. Arrowheads indicate co-localization of p16 and SPC (scale bar = 40 µm). c Percentage of p16 + (**p < 0.0001), d p16 + /SPC + (**p < 0.0001), and e SPC + cells in healthy and COPD lungs (*p = 0.0034). N = 3–11
Fig. 1 Immunohistochemical localization of p16 in human lungs. p16 (red) and SPC (yellow) staining in a healthy non-smoker, healthy smoker, and b COPD human lungs. Arrowheads indicate co-localization of p16 and SPC (scale bar = 40 µm). c Percentage of p16 + (**p < 0.0001), d p16 + /SPC + (**p < 0.0001), and e SPC + cells in healthy and COPD lungs (*p = 0.0034). N = 3–11CC BY · PubMed Central
Fig. 2 Cigarette smoke promotes p16 promoter-driven luciferase activity and senescence. a Luciferase imaging of p16−/− lungs from mice exposed to RA or CS for 4 months. b Average radiance measuring luciferase activity in p16−/− lungs (*p = 0.0114). c Luciferase staining in RA- and CS-treated lungs; images were taken of alveolar space in p16−/− mice. Arrowheads indicate luciferase-positive AECII cells and arrows indicate macrophages (scale bar = 40 µm). d Quantitative real-time PCR of p16 RNA (*p = 0.0307, **p = 0.0003) and e SA β-Gal activity measured in whole lung homogenates after 4 months of RA or CS (*p = 0.0005). N, p16+/+ RA = 4–8, p16+/+ CS = 10–14, p16−/− RA = 4–7, and p16−/− CS = 12–14 mice
Fig. 2 Cigarette smoke promotes p16 promoter-driven luciferase activity and senescence. a Luciferase imaging of p16−/− lungs from mice exposed to RA or CS for 4 months. b Average radiance measuring luciferase activity in p16−/− lungs (*p = 0.0114). c Luciferase staining in RA- and CS-treated lungs; images were taken of alveolar space in p16−/− mice. Arrowheads indicate luciferase-positive AECII cells and arrows indicate macrophages (scale bar = 40 µm). d Quantitative real-time PCR of p16 RNA (*p = 0.0307, **p = 0.0003) and e SA β-Gal activity measured in whole lung homogenates after 4 months of RA or CS (*p = 0.0005). N, p16+/+ RA = 4–8, p16+/+ CS = 10–14, p16−/− RA = 4–7, and p16−/− CS = 12–14 miceCC BY · PubMed Central
Fig. 3 p16−/− lungs maintain function and structure when challenged with CS. a Lung compliance (**p < 0.0177), pressure/volume, and area (**p < 0.0001) between the inflation and deflation limb of the PV loop measured using Flexi-Vent. b Representative Masson’s trichrome staining of lungs exposed to RA or CS (scale bar = 40 µm), mean linear intercept was determined c from these images and quantified (*p < 0.0001 and **p < 0.0001 vs. p16−/− RA). d Body weight increases over 4 months, values are the percentage increase from day 0 (*p = 0.0031, **p < 0.0001). Quantitative RT-PCR analysis e of MMP-12 (*p = 0.029 vs. p16+/+ RA, **p = 0.0077 vs. p16+/+ CS), IL-33 (*p = 0.012 vs. p16+/+ RA, **p = 0.045 vs. p16+/+ CS), and TGFβ1 (*p = 0.0021 vs. p16+/+ RA, **p = 0.0036). After 4 months of CS, all samples were normalized to mouse GAPDH. f MMP-12 (*p = 0.0004 vs. p16+/+ RA, **p = 0.0088 vs. p16+/+ CS), IL-33 (*p = 0.004 vs. p16+/+ RA, **p = 0.023 vs. p16+/+ CS, ***p = 0.0452 vs. p16−/− RA), and TGFβ1 (*p = 0.0005 vs. p16+/+ RA, **p = 0.0097, ***p = 0.0036 vs. p16+/+ RA), protein levels determined by ELISA. All protein levels are normalized to total protein in the lysate. All data is expressed as mean ± SEM, n = 4–14 mice per group
Fig. 3 p16−/− lungs maintain function and structure when challenged with CS. a Lung compliance (**p < 0.0177), pressure/volume, and area (**p < 0.0001) between the inflation and deflation limb of the PV loop measured using Flexi-Vent. b Representative Masson’s trichrome staining of lungs exposed to RA or CS (scale bar = 40 µm), mean linear intercept was determined c from these images and quantified (*p < 0.0001 and **p < 0.0001 vs. p16−/− RA). d Body weight increases over 4 months, values are the percentage increase from day 0 (*p = 0.0031, **p < 0.0001). Quantitative RT-PCR analysis e of MMP-12 (*p = 0.029 vs. p16+/+ RA, **p = 0.0077 vs. p16+/+ CS), IL-33 (*p = 0.012 vs. p16+/+ RA, **p = 0.045 vs. p16+/+ CS), and TGFβ1 (*p = 0.0021 vs. p16+/+ RA, **p = 0.0036). After 4 months of CS, all samples were normalized to mouse GAPDH. f MMP-12 (*p = 0.0004 vs. p16+/+ RA, **p = 0.0088 vs. p16+/+ CS), IL-33 (*p = 0.004 vs. p16+/+ RA, **p = 0.023 vs. p16+/+ CS, ***p = 0.0452 vs. p16−/− RA), and TGFβ1 (*p = 0.0005 vs. p16+/+ RA, **p = 0.0097, ***p = 0.0036 vs. p16+/+ RA), protein levels determined by ELISA. All protein levels are normalized to total protein in the lysate. All data is expressed as mean ± SEM, n = 4–14 mice per groupCC BY · PubMed Central
Fig. 4 SASPs and Inflammatory cytokines upregulated with CS ameliorated in p16−/− lungs. a Cytokines associated with senescent-associated secretory phenotype (SASP) and b inflammation on p16+/+ and p16−/− lungs exposed to RA or CS. IL-6 *p = 0.0499, **p = 0.0043 vs. p16+/+ CS, CXCL-1 *p = 0.0084, IL-13 *p = 0.05, **p = 0.0260, CCL-2 *p = 0.0006 vs. p16+/+ RA **p = 0.0009 vs. p16+/+ CS, RANTES *p = 0.0346, **p = 0.0267 vs. p16+/+ CS, Eotaxin *p = 0.0221 vs. p16+/+ RA, **p = 0.0010 vs. p16+/+ CS, IP-10 *p = 0.0372 vs. p16+/+ RA, **p = 0.0108, IL-5 *p = 0.0308, **p = 0.0377, IL-9 *p = 0.0425, IL-17a *p = 0.0234, **p = 0.05 vs. p16+/+ CS. N = 4–12 lungs per group
Fig. 4 SASPs and Inflammatory cytokines upregulated with CS ameliorated in p16−/− lungs. a Cytokines associated with senescent-associated secretory phenotype (SASP) and b inflammation on p16+/+ and p16−/− lungs exposed to RA or CS. IL-6 *p = 0.0499, **p = 0.0043 vs. p16+/+ CS, CXCL-1 *p = 0.0084, IL-13 *p = 0.05, **p = 0.0260, CCL-2 *p = 0.0006 vs. p16+/+ RA **p = 0.0009 vs. p16+/+ CS, RANTES *p = 0.0346, **p = 0.0267 vs. p16+/+ CS, Eotaxin *p = 0.0221 vs. p16+/+ RA, **p = 0.0010 vs. p16+/+ CS, IP-10 *p = 0.0372 vs. p16+/+ RA, **p = 0.0108, IL-5 *p = 0.0308, **p = 0.0377, IL-9 *p = 0.0425, IL-17a *p = 0.0234, **p = 0.05 vs. p16+/+ CS. N = 4–12 lungs per groupCC BY · PubMed Central
Fig. 5 Increased cell proliferation and reduced AECII senescence in p16−/− lungs. a Twenty-four hours post IP EdU injection (50 mg/kg), p16+/+ and p16−/− lungs exposed to RA and CS were fixed and stained with Click-It EdU (green), SPC (yellow), Podoplatin (PDPN, red), and DAPI (blue, scale bar = 30 µm). b Quantification of lung proliferating (EdU+) cells in the alveolar airspace. At least 1500 nuclei per airspace were counted in each lung *p = 0.0197, **p < 0001. N = 4–12 lungs per group. c Percentage of SPC+ cells in the alveolar region of the lung *p = 0.015, **p = 0.0004. d Images of Isolated AECIIs from p16+/+ and p16−/− lungs treated with 5% CSE in 10% serum for 24 h and probed for β-galactosidase activity using C12FDG substrate (scale bar = 400 µm). e AECIIs immunostained with SPC (red) and DAPI (blue). f Flow cytometry analysis of AECII measuring purity of isolation. X axis is measuring EPCAM for epithelial cell specificity and y axis is measuring SPC for AECII specificity. g AECIIs treated with 5% CSE and C12FDG, and quantified with flow cytometry. Data represent the average ± SEM of four to five independent experiments
Fig. 5 Increased cell proliferation and reduced AECII senescence in p16−/− lungs. a Twenty-four hours post IP EdU injection (50 mg/kg), p16+/+ and p16−/− lungs exposed to RA and CS were fixed and stained with Click-It EdU (green), SPC (yellow), Podoplatin (PDPN, red), and DAPI (blue, scale bar = 30 µm). b Quantification of lung proliferating (EdU+) cells in the alveolar airspace. At least 1500 nuclei per airspace were counted in each lung *p = 0.0197, **p < 0001. N = 4–12 lungs per group. c Percentage of SPC+ cells in the alveolar region of the lung *p = 0.015, **p = 0.0004. d Images of Isolated AECIIs from p16+/+ and p16−/− lungs treated with 5% CSE in 10% serum for 24 h and probed for β-galactosidase activity using C12FDG substrate (scale bar = 400 µm). e AECIIs immunostained with SPC (red) and DAPI (blue). f Flow cytometry analysis of AECII measuring purity of isolation. X axis is measuring EPCAM for epithelial cell specificity and y axis is measuring SPC for AECII specificity. g AECIIs treated with 5% CSE and C12FDG, and quantified with flow cytometry. Data represent the average ± SEM of four to five independent experimentsCC BY · PubMed Central
Fig. 6 Increased IGF1 signaling in p16−/− lungs. a Heat map of 84 insulin-related genes in lungs treated with CS. Genes in blue are reduced, while genes in yellow are increased. N = 5 lungs per group. b IGF RNA levels measured by TAQman qPCR. *p = 0.016, **p = 0.007, ***p = 0.008. c IGF1 measured by ELISA from whole lung lysates. *p = 0.0028, **p = 0.0421 vs. + /+ CS. d Phospho-insulin receptor measured by ELISA (*p = 0.0085). e Levels of key proliferation signaling genes Akt1 (*p = 0.0137, **p = 0.0011), Pparγ (*p = 0.0009, **p = 0.0392), and MapK1 (*p < 0.0001, **p = 0.039) from profiler array. N = 5 lungs per group
Fig. 6 Increased IGF1 signaling in p16−/− lungs. a Heat map of 84 insulin-related genes in lungs treated with CS. Genes in blue are reduced, while genes in yellow are increased. N = 5 lungs per group. b IGF RNA levels measured by TAQman qPCR. *p = 0.016, **p = 0.007, ***p = 0.008. c IGF1 measured by ELISA from whole lung lysates. *p = 0.0028, **p = 0.0421 vs. + /+ CS. d Phospho-insulin receptor measured by ELISA (*p = 0.0085). e Levels of key proliferation signaling genes Akt1 (*p = 0.0137, **p = 0.0011), Pparγ (*p = 0.0009, **p = 0.0392), and MapK1 (*p < 0.0001, **p = 0.039) from profiler array. N = 5 lungs per groupCC BY · PubMed Central
Fig. 7 Diminished IGF1 and Akt mRNA in human COPD lungs and loss of p16 increases Akt signaling in CS-exposed lungs. a, b Gene microarray analysis of whole lung lysates from 9 normal and 94 COPD donors **p = .85e−6. c–e Protein profile of phosphor-Akt Thr308 (*p = 0.0359), total Akt (*p = 0.0396, **p = 0.0416), and Cyclin D (**p = 0.0249). f Representative western blotting of whole lung lysates exposed to RA and CS (n = 4–6). g Representative images of fibroblasts isolated from p16+/+ and p16−/− lungs then treated with DMSO or Akt I (10 μM, scale bar = 400 µm). h QPCR was performed to determine Cyclin D gene expression. Data are expressed as the average ± SEM of at least three independent experiments, *p = 0.0471, **p = 0.0230, ***p < 0.0001, #p = 0.001
Fig. 7 Diminished IGF1 and Akt mRNA in human COPD lungs and loss of p16 increases Akt signaling in CS-exposed lungs. a, b Gene microarray analysis of whole lung lysates from 9 normal and 94 COPD donors **p = .85e−6. c–e Protein profile of phosphor-Akt Thr308 (*p = 0.0359), total Akt (*p = 0.0396, **p = 0.0416), and Cyclin D (**p = 0.0249). f Representative western blotting of whole lung lysates exposed to RA and CS (n = 4–6). g Representative images of fibroblasts isolated from p16+/+ and p16−/− lungs then treated with DMSO or Akt I (10 μM, scale bar = 400 µm). h QPCR was performed to determine Cyclin D gene expression. Data are expressed as the average ± SEM of at least three independent experiments, *p = 0.0471, **p = 0.0230, ***p < 0.0001, #p = 0.001CC BY · PubMed Central
Fig. 8 Proposed mechanism of protection. In the presence of chronic CS, p16 levels increase and cells become senescent. CS induces pro-inflammatory cytokines throughout the lung, and in the senescent cells SASPs are secreted, which perpetuate senescence and alveolar destruction (right side). When the cell cycle inhibitor p16 is not present (left side), basal levels of IGF1 are upregulated, resulting in stimulated insulin receptors and activation of Akt. Activated Akt stimulates cell proliferation evidenced by increases in Cyclin D expression and the maintenance of healthy alveoli
Fig. 8 Proposed mechanism of protection. In the presence of chronic CS, p16 levels increase and cells become senescent. CS induces pro-inflammatory cytokines throughout the lung, and in the senescent cells SASPs are secreted, which perpetuate senescence and alveolar destruction (right side). When the cell cycle inhibitor p16 is not present (left side), basal levels of IGF1 are upregulated, resulting in stimulated insulin receptors and activation of Akt. Activated Akt stimulates cell proliferation evidenced by increases in Cyclin D expression and the maintenance of healthy alveoliCC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 59 references

Cited by

See all 81

Metadata

Authors
Cottage, C. T., Peterson, N., Kearley, J., Berlin, A., Xiong, X., Huntley, A., Zhao, W., Brown, C., Migneault, A., Zerrouki, K., Criner, G., Kolbeck, R., Connor, J., & Lemaire, R.
Affiliations
  • AstraZeneca (United States) (US)
  • Temple Lung Center (US)
Corresponding author
Cottage, Christopher T.
Venue
Communications Biology
Published
2019-08-09
Volume
2
Issue
1
Pages
307-307
ISSN
2399-3642 (ISSN-L)
OpenAlex
W2969184781
Cited by
71
References
58
Citations by year
2026: 12 · 2025: 10 · 2024: 13 · 2023: 12 · 2022: 9 · 2021: 8 · 2020: 7
FWCI
4.41
Type
journal article
Language
en
Open access
Licence
Locations
  • Communications Biology (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
AstraZeneca
Topics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Telomeres, Telomerase, and Senescence
  • Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Smoking Behavior and Cessation
Keywords
cellular senescence, p16, cigarette smoke, emphysema, chronic obstructive pulmonary disease, alveolar type II cells, alveolar progenitor cells, alveolar regeneration, DNA damage, lung stem cells
MeSH terms
Animals, Emphysema, Insulin-Like Growth Factor I, Lung, Mice, Inbred C57BL, Models, Biological, Promoter Regions, Genetic, RNA, Messenger, Smoking, Signal Transduction, Cytokines, Cellular Senescence, Cyclin-Dependent Kinase Inhibitor p16, Pulmonary Disease, Chronic Obstructive, Cell Proliferation, Proto-Oncogene Proteins c-akt, Alveolar Epithelial Cells

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Targeting p16-induced senescence prevents cigarette smoke-induced emphysema by promoting IGF1/Akt1 signaling in mice. https://app.cochat.ai/papers/10.1038/s42003-019-0532-1
The paper
Cottage, C. T., Peterson, N., Kearley, J., Berlin, A., Xiong, X., Huntley, A., Zhao, W., Brown, C., Migneault, A., Zerrouki, K., Criner, G., Kolbeck, R., Connor, J., & Lemaire, R. (2019). Targeting p16-induced senescence prevents cigarette smoke-induced emphysema by promoting IGF1/Akt1 signaling in mice. Communications Biology. https://doi.org/10.1038/s42003-019-0532-1

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.